Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial-Reference-Cited by-同舟云学术

Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial

Published:2014-12 Issue:4 Volume:53 Page:265-271
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

Calvaruso Giusi,Vitrano Angela,Di Maggio Rosario,Ballas Samir,Steinberg Martin H.,Rigano Paolo,Sacco Massimiliano,Telfer Paul,Renda Disma,Barone Rita,Maggio Aurelio

Funder

Foundation Franco and Piera Cutino

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference31 articles.

1. The management of sickle cell disease;National Institutes of Health NHLBI,2002

2. Best practices for transfusion for patients with sickle cell disease;Wun;Hematol. Rep.,2009

3. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography;Adams;N. Engl. J. Med.,1998

4. Optimizing primary stroke prevention in sickle cell anemia (stop 2) trial investigators discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease;Adams;N. Engl. J. Med.,2005

5. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease;Ballas;Semin. Hematol.,2001

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Compare the Efficacy and Safety of Deferoxamine, Deferasirox, and Deferiprone in Patients With Sickle Cell Disease or Transfusion-Dependent Anemia: A Network Meta-Analysis of Randomized Control Trials;Cureus;2024-02-05

2. Efficacy and safety of early‐start deferiprone in infants and young children with transfusion‐dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double‐blind, placebo‐controlled, clinical trial (START);American Journal of Hematology;2023-07-04

3. Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives;Journal of Blood Medicine;2023-04

4. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia;Cochrane Database of Systematic Reviews;2023-03-06

5. An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes;Expert Review of Hematology;2023-02-01